Species |
Human |
Protein Construction |
GRO-β (Ala35-Asn107) Accession # P19875 |
|
Purity |
> 95% as analyzed by SDS-PAGE |
Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
Biological Activity |
The EC50 value of human GRO beta on Ca2+ mobilization assay in CHO-K1/Gα15/hCXCR2 cells (human Gα15 and human CXCR2 stably expressed in CHO-K1 cells) is less than 200.0 ng/ml. |
Expression System |
E. coli |
Apparent Molecular Weight |
~8 kDa, on SDS-PAGE under reducing conditions. |
Formulation |
Lyophilized after extensive dialysis against PBS. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
Target Background |
Human GRO-α, GRO-β (MIP-2α), and GRO-γ (MIP-2β) are products of three distinct, nonallelichuman genes. GRO-β and GRO-γ share 90% and 86% amino acid sequence homology, respectively, with GROα. All three isoforms of GRO are CXC chemokines that can signal through the CXCR1 or CXCR2 receptors.GRO expression is inducible by serum or PDGF and/or by a variety of inflammatory mediators, such as IL-1 and TNF, in monocytes, fibroblasts, melanocytes and epithelial cells. In certain tumor cell lines, GRO is expressed constitutively.Similar to other alpha chemokines, the three GRO proteins are potent neutrophil attractants and activators. In addition, these chemokines are also active toward basophils. |
Synonyms |
Growth Regulated Protein/Melanoma Growth Stimulatory Activity (MGSA β); CXCL2; MIP-2α; GRO2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.